We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · January 16, 2020

An Evaluation of Serum sHER2, CA15.3, and CEA Levels as Biomarkers for Response of Metastatic Breast Cancer to Trastuzumab-Based Therapies

PloS One

 

Additional Info

PloS One
An Updated Evaluation of Serum sHER2, CA15.3, and CEA Levels as Biomarkers for the Response of Patients With Metastatic Breast Cancer to Trastuzumab-Based Therapies
PLoS ONE 2020 Jan 01;15(1)e0227356, A Perrier, PY Boelle, Y Chrétien, J Gligorov, JP Lotz, D Brault, E Comperat, G Lefèvre, M Boissan

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading